æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¶àëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬£¬£¬ £¬ÂȵªÆ½"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬£¬£¬ £¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£»£»£»£» £» £»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬£¬£¬ £¬ÂȵªÆ½"/> æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¶àëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ-½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬£¬£¬ £¬ÂȵªÆ½"/> ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú-ÒøÐÓÒ¶£¬£¬£¬£¬£¬£¬ £¬ÂȵªÆ½ ÒøÐÓÒ¶,Þ½ÏãÕýÆøË®,ŵ·úɳÐÇ,ÂȵªÆ½,ÑÎËáÂȱûàº,С¶ùÖ¹¿ÈÌǽ¬,Í·æß¿ËÂå¿ÅÁ£,ºìÂÝÃ¹ËØ¿ÅÁ£,Å£»£»£»£» £» £»ÇËá¿ÅÁ£,Í´¾­Äþ¿ÅÁ£,ÐÂÉú»¯¿ÅÁ£,°¢¹éÑøÑªÌǽ¬,½ðÒø»¨Â¶"/>

½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

æÇÃÀGLP-1¶àëĹú¼ÊÃ÷ÐDzúÆ·£¡½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¶àëÄÐÂÒ©ÔÚ·ÊÅÖÖÎÁÆÁìÓòÈ¡µÃÁÙ´²Ç°ÐÂÍ»ÆÆ

ÈÕÆÚ£º

2026Äê04ÔÂ02ÈÕ 14:40


ÔÚ·ÊÅÖ¼°Ïà¹Ø´úлÐÔ¼²²¡³ÉΪȫÇòÐÔ¿µ½¡Ìôսȷµ±Ï£¬£¬£¬£¬£¬£¬ £¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú£¨ÒÔϼò³Æ“½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú”£©´«À´Õñ·ÜÈËÐĵÄÐÂÎÅ£¡Æä×ÔÖ÷Ñз¢µÄÁ¢ÒìС·Ö×Ó»·ëÄÒ©ÎMCR»·ëÄ£©£¬£¬£¬£¬£¬£¬ £¬ÔÚÕë¶ÔDB/DB·ÊÅÖСÊóÄ£×ÓµÄÁÙ´²Ç°Ñо¿ÖУ¬£¬£¬£¬£¬£¬ £¬Õ¹ÏÖ³öÓÅÓÚÏÖÓÐÃ÷ÐÇÒ©ÎïGLP-1¶àëĵļõÖØÐ§¹û£»£»£»£» £» £»ÍŽáÆä¶Ô¼¡ÈâµÄ¼á³Ö×÷Ó㬣¬£¬£¬£¬£¬ £¬ÒÔ¼°¶ÔѪÌÇ¡¢ÑªÖ¬µÈ´úлָ±êµÄ×ۺϵ÷Àí×÷Ó㬣¬£¬£¬£¬£¬ £¬ÓÐÍû´øÀ´²î±ð»¯µÄÁÙ´²Ñ¡Ôñ¡£¡£¡£¡£¡£

Ò»¡¢¾ªÑ޵ļõÖØÊý¾Ý

DB/DBСÊóÊÇÑо¿·ÊÅÖºÍ2ÐÍÌÇÄò²¡µÄ¾­µä¶¯ÎïÄ£×Ó£¬£¬£¬£¬£¬£¬ £¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ£¬£¬£¬£¬£¬£¬ £¬ÌåÏÖ³öÑÏÖØµÄ·ÊÅÖ¡¢¸ßѪÌǺʹúлÔÓÂÒµÈÖ¢×´¡£¡£¡£¡£¡£ÔÚ½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¿ªÕ¹µÄÕâÏîÁÙ´²Ç°Ñо¿ÖУ¬£¬£¬£¬£¬£¬ £¬¹«Ë¾×ÔÑеÄС·Ö×Ó»·ëÄÕ¹ÏÖ³öÓÅÒìµÄ¼õÖØÐ§¹û¡£¡£¡£¡£¡£

ÊÔÑéЧ¹ûÏÔʾ£¬£¬£¬£¬£¬£¬ £¬¾­ÓÉΪÆÚ8ÖܵÄÖÎÁÆ£¬£¬£¬£¬£¬£¬ £¬Óë¿Õȱ±ÈÕÕ×éDB/DBСÊóÏà±È£¬£¬£¬£¬£¬£¬ £¬MCR»·ëĽϸ߼ÁÁ¿×éµÄСÊóµÄÌåÖØÏ½µ·ù¶ÈԼΪGLP-1¶àëÄ×éµÄ1.25±¶£¬£¬£¬£¬£¬£¬ £¬Ê¹DB/DBСÊóµÄÌåÖØÔöÌíÇ÷ÊÆÏÔ×Å·Å»º£¬£¬£¬£¬£¬£¬ £¬¿¿½ü¿µ½¡±ÈÕÕ×éˮƽ¡£¡£¡£¡£¡£

 

 

¶þ¡¢¶àÏî´úлָ±êÖÜÈ«¸ÄÉÆ

MCR»·ëĽϸ߼ÁÁ¿×éÔÚ¸ÄÉÆ¸ÊÓÍÈýõ¥£¨TG£©¡¢¸ßÃܶÈÖ¬ÂѰ׵¨¹Ì´¼£¨HDL-C£©¡¢ÑªÌÇ¡¢ÄòÌÇˮƽ·½Ã棬£¬£¬£¬£¬£¬ £¬Í¬ÑùÌåÏÖÓÅÒ죺

1.TGˮƽ£ºÏÔÖø½µµÍDB/DBСÊóµÄTGˮƽ£¬£¬£¬£¬£¬£¬ £¬ÓÅÓÚGLP-1¶àëÄ×飻£»£»£» £» £»

2.HDL-Cˮƽ£ºÏÔ×ÅÉý¸ß£¬£¬£¬£¬£¬£¬ £¬ÓÅÓÚGLP-1¶àëÄ×飻£»£»£» £» £»ÓÐÖúÓÚ½µµÍ¶¯ÂöÖàÑùÓ²»¯Î£º¦£»£»£»£» £» £»

3.ѪÌÇˮƽ£ºÖÎÁÆ6ÖܵĽµµÍѪÌÇŨ¶ÈˮƽÓëGLP-1¶àëÄ×é¿¿½ü£»£»£»£» £» £»

4.ÄòÌÇˮƽ£ºÖÎÁÆ8Öܽ«ÄòÌÇˮƽ´Ó»ùÏß½µÖÁÒ»°ë£»£»£»£» £» £»

5.ÌÇ»¯ÑªºìÂѰף¨HbA1c£©£ºÓëÄ£×Ó×éÏà±È£¬£¬£¬£¬£¬£¬ £¬HbA1cϽµ·ù¶È´ïÔ¼1/3¡£¡£¡£¡£¡£

|ÍŽáDZÁ¦

ÖµµÃÒ»ÌáµÄÊÇ£¬£¬£¬£¬£¬£¬ £¬½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚÒÑ¿ªÕ¹ÁË»·ëÄÓëGLP-1ÀàÒ©ÎÈçGLP-1¶àëÄ£©ÍŽáʹÓõÄÑо¿£¬£¬£¬£¬£¬£¬ £¬Ð§¹ûÏÔʾÔÚÒûʳÓÕµ¼µÄ·ÊÅÖСÊóÄ£×ÓÖУ¬£¬£¬£¬£¬£¬ £¬Á½ÕßÔÚ¼õÖØÐ§¹û¼°¼¡Èâ±£»£»£»£» £» £»¤·½Ãæ¾ßÓÐÃ÷È·µÄЭͬЧӦ£º

1.Эͬ¼õÖØ£ºÁªÊÊÓÃÒ©×éÌåÏÖ³ö¸üÏÔÖøµÄ¼õÖØÐ§¹û£¬£¬£¬£¬£¬£¬ £¬ÓÅÓÚµ¥Ò©ÖÎÁÆ£»£»£»£» £» £»

2.ïÔÌ­¼¡ÈâÁ÷ʧ£º»·ëÄÔÚÁªÓÃÖÐÓÐÓûº½âGLP-1ÀàÒ©Îï´øÀ´µÄ¼¡ÈâÁ÷ʧÎÊÌ⣬£¬£¬£¬£¬£¬ £¬Ìá¸ßÕûÌåÖÎÁÆÇå¾²ÐÔ¡£¡£¡£¡£¡£

Èý¡¢¶à°ÐµãЭͬ×÷Ó㺻·ëĵÄÁ¢Òì»úÖÆ

MCR»·ëÄÖ®ÒÔÊÇÄܹ»ÔÚ¼õÖØ¼°ÆäËû´úлָ±êÉÏÈ¡µÃÔÆÔÆÓÅÒìµÄЧ¹û£¬£¬£¬£¬£¬£¬ £¬ÓëÆäÆæÒìµÄ×÷ÓûúÖÆÃܲ»¿É·Ö¡£¡£¡£¡£¡£×÷ΪһÖÖС·Ö×Ó»·ëÄÒ©Î£¬£¬£¬£¬£¬ £¬Äܹ»Í¬Ê±¾«×¼×÷ÓÃÓÚMC4RºÍMC1RÁ½¸öÒªº¦°Ðµã£¬£¬£¬£¬£¬£¬ £¬Í¨¹ý¶à°ÐµãЭͬ×÷Ó㬣¬£¬£¬£¬£¬ £¬Ê©Õ¹Æä׿ԽµÄ´úлµ÷Àí¹¦Ð§¡£¡£¡£¡£¡£

|¼¤»îMC4R£ºÒÖÖÆÊ³Óû£¬£¬£¬£¬£¬£¬ £¬Ôö½øÖ¬·¾ÆÊÎö

MC4RÊÇÖÐÊàÉñ¾­ÏµÍ³µ÷¿ØÄÜÁ¿Æ½ºâµÄÒªº¦ÊÜÌå¡£¡£¡£¡£¡£½ñÄê»á¹ÙÍøµÇ¼Èë¿ÚMCR»·ëÄ×÷ΪMC4R¼¤¶¯¼Á£¬£¬£¬£¬£¬£¬ £¬Äܹ»Ôö½øÖ¬·¾ÆÊÎö£¬£¬£¬£¬£¬£¬ £¬ÒÖÖÆÖ¬·¾ÌìÉú£»£»£»£» £» £»Ôö½ø°×ɫ֬·¾×éÖ¯ºÖ±ä£»£»£»£» £» £»Ìá¸ßÒȵºËØÃô¸ÐÐÔ£»£»£»£» £» £»ÔÚ²»ÏÔÖøÒÖÖÆÊ³ÓûµÄÌõ¼þÏÂʵÏÖ¼õÖ¬£¬£¬£¬£¬£¬£¬ £¬×èÖ¹Ñáʳ¸±×÷ÓÃ1¡£¡£¡£¡£¡£

 

 

|¼¤»îMC1R:¿¹Ñ×ÃâÒßµ÷Àí£¬£¬£¬£¬£¬£¬ £¬»Ö¸´ÊÝËØÃô¸ÐÐÔ

MC1RÖ÷Òª¼ÓÈëÃâÒßµ÷ÀíºÍÑ×Ö¢·´Ó¦¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R£¬£¬£¬£¬£¬£¬ £¬Äܹ»ÏÔÖø¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬£¬£¬£¬£¬£¬ £¬½µµÍÑ×Ö¢Òò×Ó£¨°üÀ¨IL-1, TNF-a, IL-6, IL-8, and IL-12, iNOSµÈ£©µÄ±í´ï´Ó¶ø»Ö¸´ÊÝËØÃô¸ÐÐԺ͵÷ÀíÃâÒß·´Ó¦£¬£¬£¬£¬£¬£¬ £¬¶Ô×ÔÉíÃâÒßÐÔ¼²²¡¾ßÓÐDZÔÚÖÎÁƼÛÖµ2¡£¡£¡£¡£¡£

ËÄ¡¢ÁÉÀ«µÄÓ¦ÓÃÔ¶¾°£º´úлÔÓÂÒÓë×ÔÉíÃâÒß˳Ӧ֢

»ùÓÚMCR»·ëÄÔÚÁÙ´²Ç°Ñо¿ÖÐÕ¹ÏÖ³öµÄ׿Խ¼õÖØÐ§¹ûºÍ¶àϵͳ´úл¸ÄÉÆ×÷Ó㬣¬£¬£¬£¬£¬ £¬½ñÄê»á¹ÙÍøµÇ¼Èë¿Ú¶ÔÆäδÀ´ÔÚ´úлºÍ×ÔÃâÁìÓòÖеÄÓ¦ÓÃÔ¶¾°³äÂúÐÅÐÄ¡£¡£¡£¡£¡£

´úл×ÛºÏÕ÷¼°Æä²¢·¢Ö¢·½Ã棬£¬£¬£¬£¬£¬ £¬MCR»·ëIJ»µ«ÄܼõÖØ£¬£¬£¬£¬£¬£¬ £¬»¹ÄÜͬ²½¸ÄÉÆÑªÌÇ¡¢ÑªÖ¬¡¢HbA1c¡¢ÄòÌǵȶàÏîÖ¸±ê£¬£¬£¬£¬£¬£¬ £¬¶Ô2ÐÍÌÇÄò²¡¡¢·Ç¾Æ¾«ÐÔÖ¬·¾ÐԸβ¡¡¢¸ßѪѹ¡¢¶¯ÂöÖàÑùÓ²»¯µÈ´úл×ÛºÏÕ÷×é·ÖÖ®Ò»»ò¶àÏî¾ßÓиÉԤDZÁ¦¡£¡£¡£¡£¡£

×ÔÉíÃâÒßÓëÑ×Ö¢Ïà¹Ø¼²²¡·½Ã棬£¬£¬£¬£¬£¬ £¬ÓÉÓÚÆä¾ß±¸ÏÔÖøµÄ¿¹Ñ׺ÍÃâÒßµ÷Àí×÷Ó㬣¬£¬£¬£¬£¬ £¬Î´À´ÓÐÍûÍØÕ¹ÖÁÀà·çʪÐÔÊàŦÑ×£»£»£»£» £» £»ÂýÐÔÉö²¡£¡£¡£¡£¡£¨CKD£©£»£»£»£» £» £»ÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¨DN£©µÈ˳Ӧ֢¡£¡£¡£¡£¡£

½ÓÏÂÀ´£¬£¬£¬£¬£¬£¬ £¬¹«Ë¾½«¼ÌÐøÍÆ¶¯¶àëÄÐÂÒ©µÄÁÙ´²Ç°Ò©ÀíѧºÍ¶¾ÀíѧÑо¿£¬£¬£¬£¬£¬£¬ £¬ÕùÈ¡ÔçÈÕ½«ÐÂÒ©ÍÆÏòÁÙ´²½×¶Î£¬£¬£¬£¬£¬£¬ £¬ÔÚÒÑÊÚȨµÄרÀû¼Ó³ÖÏ£¬£¬£¬£¬£¬£¬ £¬¿ìËÙ½«²î±ð»¯µÄºÃÒ©´ø¸øÓµÓÐÏà¹ØÖÎÁÆÐèÇóµÄ»¼ÕßȺÌå¡£¡£¡£¡£¡£

ÎÄÕÂȪԴÓÚҩʱ´ú¹«ÖÚºÅ

²Î¿¼ÎÄÏ×

1. Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022). Signaling pathways in obesity: mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 7(1), 298.https://doi.org/10.1038/s41392-022-01149-x

2. Mun, Y., Kim, W., & Shin, D. (2023). Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. International journal of molecular sciences, 24(15),12152. https://doi.org/10.3390/ijms241512152

Ïà¹ØÍÆ¼ö

ÍøÕ¾µØÍ¼